Related references
Note: Only part of the references are listed.Topology impacts TRAIL therapy: Differences in primary cancer growth and liver metastasis between orthotopic and subcutaneous xenotransplants of pancreatic ductal adenocarcinoma cells
Bastian Kettler et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2021)
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview
Francisco Quinonero et al.
CANCER BIOLOGY & MEDICINE (2019)
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
Andrew McGuigan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery
Chih-Po Hsu et al.
IN VIVO (2018)
CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response
Abdul S. Qadir et al.
CELL REPORTS (2017)
Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs)
Li Wang et al.
PLOS ONE (2017)
CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy
Shujie Zhao et al.
CLINICAL CANCER RESEARCH (2016)
Current Standard and Future Perspectives in First and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma
Volker Ellenrieder et al.
DIGESTION (2016)
Gemcitabine-induced CXCL8 expression counteracts its actions by inducing tumor neovascularization
Yao Song et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma
M. Teodorczyk et al.
CELL DEATH AND DIFFERENTIATION (2015)
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Yoav Binenbaum et al.
DRUG RESISTANCE UPDATES (2015)
CD95 and CD95L promote and protect cancer stem cells
Paolo Ceppi et al.
NATURE COMMUNICATIONS (2014)
An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through upregulation of CXCR4
Sumit Arora et al.
CANCER RESEARCH (2013)
TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells
Dong-Hui Zhou et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2013)
Inhibition of Nuclear Factor Kappa-B Enhances the Antitumor Effect of Combination Treatment with Tumor Necrosis Factor-Alpha Gene Therapy and Gemcitabine for Pancreatic Cancer in Mice
Yuki Fujiwara et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2013)
Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition
Karl Quint et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion
Ernst J. A. Steller et al.
EMBO REPORTS (2011)
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
S. Singh et al.
BRITISH JOURNAL OF CANCER (2010)
The Role of MMP7 and Its Cross-Talk with the FAS/FASL System during the Acquisition of Chemoresistance to Oxaliplatin
Vanessa Almendro et al.
PLOS ONE (2009)
Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice
Jan-Hendrik Egberts et al.
CANCER BIOLOGY & THERAPY (2008)
Yes and PI3K bind CD95 to signal invasion of glioblastoma
Susanne Kleber et al.
CANCER CELL (2008)
Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis
Jan-Hendrik Egberts et al.
CANCER RESEARCH (2008)
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
A. Trauzold et al.
ONCOGENE (2006)
NF-κB in solid tumors
Francesco Pacifico et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells
N Ishimura et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
CD95 and TRAF2 promote invasiveness of pancreatic cancer cells
A Trauzold et al.
FASEB JOURNAL (2005)
NF-κB functions as a tumour promoter in inflammation-associated cancer
E Pikarsky et al.
NATURE (2004)
Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation
CE Rübe et al.
RADIOTHERAPY AND ONCOLOGY (2004)
Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: A novel adjuvant treatment strategy for pancreatic ductal carcinoma
J Tepel et al.
PANCREAS (2004)
Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells
A Trauzold et al.
BRITISH JOURNAL OF CANCER (2003)
Fas engagement induces neurite growth through ERK activation and p35 upregulation
J Desbarats et al.
NATURE CELL BIOLOGY (2003)
NF-kappa B at the crossroads of life and death
M Karin et al.
NATURE IMMUNOLOGY (2002)
Regulation of FasL by NF-κB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells
FG Harwood et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
